Why the study?
The study was conducted to analyze specialized literature regarding the effect of type 2 diabetes mellitus on the cardiac conduction system in patients with a permanent pacemaker.
Type 2 diabetes complicates the management of patients with permanent pacemakers by increasing the risk of arrhythmias and heart failure progression, necessitating further research into optimal hypoglycemic therapies with antiarrhythmic properties.
Aim – to analyse specialized literature and study the effect of type 2 diabetes mellitus on the cardiac conduction system in patients with a permanent pacemaker.Conclusions. The complex, multifactorial pathogenesis of diabetes mellitus complicates the study of the relationship between the presence of this metabolic disease and arrhythmia. It is now evident that hyper- and hypoglycemia, variations in blood glucose levels can provoke the development of arrhythmias, including atrial fibrillation (AF). Changes in the heart architecture are responsible for electrical conduction slowing or acceleration and pulse transmission interruption. It is proved that the presence of type 2 diabetes mellitus increases the likelihood of heart failure progression. Further studies would be able to give an answer regarding the prognostic value of type 2 diabetes influence on the results of cardiac pacing after a device implantation, as well as to determine the most effective hypoglycemic drugs with antiarrhythmic properties which can prevent the development of AF recurrence, help slow down the progression of heart failure and possibly reduce a mortality rate among this group of patients.
No takes yet. Share an insight, caveat, or question.
Brynza et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: